NCT06179446View on ClinicalTrials.gov

A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

December 13, 2023

Primary Completion Date

September 25, 2025

Study Completion Date

September 25, 2025

Conditions
GrippeInfluenzaVaccines
Interventions
BIOLOGICAL

pdmFlu vaccine

Intramuscular injection

BIOLOGICAL

Placebo

Intramuscular injection

BIOLOGICAL

Licensed influenza vaccine

Intramuscular injection

Trial Locations (4)

10016

NYU Langone Health, New York

33024

Research Centers of America ( Hollywood ), Hollywood

Research Centers of America, Hollywood

06511

Pfizer Clinical Research Unit - New Haven, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY